![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/en/news-release/2024/07/09/2910296/0/en/Sutro-Biopharma-Appoints-Dr-Barbara-Leyman-as-Chief-Business-Development-Officer.html
https://www.prnewswire.com/news-releases/vgxi-inc-announces-a-strategic-partnership-with-sutro-biopharma-inc-to-support-growing-clinical-pipeline-302161526.html
https://www.globenewswire.com/news-release/2024/05/13/2880903/0/en/Sutro-Biopharma-Reports-First-Quarter-2024-Financial-Results-Business-Highlights-and-Select-Anticipated-Milestones.html
https://www.globenewswire.com/news-release/2024/04/30/2872188/0/en/Sutro-Biopharma-Announces-Initiation-of-Randomized-Portion-Part-2-of-REFR%CE%B1ME-O1-Trial.html
https://www.ipsen.com/press-releases/ipsen-and-sutro-biopharma-announce-exclusive-global-licensing-agreement-for-an-adc-targeting-solid-tumors/
https://www.globenewswire.com/news-release/2024/04/02/2855747/0/en/Sutro-Biopharma-Announces-Pricing-of-75-Million-Underwritten-Offering.html
https://www.globenewswire.com/news-release/2024/03/25/2852012/0/en/Sutro-Biopharma-Reports-Full-Year-2023-Financial-Results-Business-Highlights-and-Select-Anticipated-Milestones.html
https://www.globenewswire.com//news-release/2024/02/06/2824717/0/en/Sutro-Biopharma-to-Participate-in-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/01/04/2804329/0/en/Sutro-Biopharma-Highlights-Potential-Multi-Cancer-Opportunity-for-Luvelta-a-FolR%CE%B1-targeting-ADC.html
https://www.globenewswire.com//news-release/2023/12/14/2796695/0/en/Sutro-Biopharma-to-Host-Investor-Webcast-Highlighting-Potential-Multi-Cancer-Opportunity-for-Luvelta-a-FolR%CE%B1-targeted-ADC-on-January-4-2024.html